Activity-based probes for functional interrogation of retaining β-glucuronidases by Wu, Liang et al.
This is an author produced version of Activity-based probes for functional interrogation of 
retaining β-glucuronidases.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/117420/
Article:
Wu, Liang orcid.org/0000-0003-0294-7065, Jiang, Jianbing orcid.org/, Jin, Yi 
orcid.org/0000-0002-6927-4371 et al. (12 more authors) (2017) Activity-based probes for 
functional interrogation of retaining β-glucuronidases. NATURE CHEMICAL BIOLOGY. pp. 
867-873. ISSN 1552-4450 
https://doi.org/10.1038/nchembio.2395
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
Activity based probes for functional interrogation of 1 
retaining E-glucuronidases 2 
Liang Wu
§#
, Jianbing Jiang
ΐ#
, Yi Jin
§#
, Wouter W. Kallemeijn
Ώ
, Chi-Lin Kuo
Ώ
, Marta Artola
ΐ
, 3 
Wei Dai
ΐ
, Cas van Elk
ΐ
, Marco van Eijk
Ώ
, Gijsbert A. van der Marel
ΐ
, Jeroen D. C. Codée
ΐ
, 4 
Bogdan I. Florea
ΐ
, Johannes M. F. G. Aerts
Ώ
, Herman S. Overkleeft
ΐ*
, Gideon J. Davies
§*
 5 
 ?Department of Bioorganic Synthesis, Leiden Institute of Chemistry, Leiden University, P.O. 6 
Box 9502, 2300 RA Leiden, the Netherlands 7 
 ?Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, P.O. 8 
Box 9502, 2300 RA Leiden, the Netherlands 9 
§York Structural Biology Laboratory, Department of Chemistry, University of York, 10 
Heslington, York, YO10, 5DD, UK 11 
 12 
# L.W., J.J. and Y.J. contributed equally to this work 13 
Corresponding authors: gideon.davies@york.ac.uk; h.s.overkleeft@chem.leidenuniv.nl 14 
  15 
Abstract 16 
Humans express at least two distinct E-glucuronidase enzymes involved in disease: exo-acting E-17 
glucuronidase (GUSB), whose deficiency gives rise to mucopolysaccharidosis type VII, and endo-18 
acting heparanase (HPSE), implicated in inflammation and cancers. The medical importance of these 19 
enzymes necessitates reliable methods to assay their activities in tissues. Herein, we present a set of 20 
E-glucuronidase specific activity based probes (ABPs) which allow for rapid and quantitative 21 
visualization of GUSB and HPSE in biological samples, providing a powerful tool for dissecting their 22 
activities in normal and disease states.  Unexpectedly, we find that the supposedly inactive HPSE 23 
proenzyme proHPSE is also labeled by our ABPs, leading to surprising insights regarding structural 24 
relationships between proHPSE, mature HPSE, and their bacterial homologs.  Our results 25 
demonstrate the application of E-glucuronidase ABPs in tracking pathologically relevant enzymes, 26 
and provide a case study of how ABP driven approaches can lead to discovery of unanticipated 27 
structural and biochemical functionality. 28 
Introduction  29 
Retaining E-glucuronidases are enzymes responsible for hydrolytic cleavage of E-linked glucuronides 30 
from polysaccharide and glycoconjugate molecules, with net retention of anomeric stereochemistry 31 
at the released glucuronide.  Humans express at least two major retaining E-glucuronidases: exo-32 
acting GUSB, responsible for cleaving E-linked glucuronides from the non-reducing end of diverse 33 
glycosaminoglycans (GAGs) in the lysosome, and endo-acting heparanase (HPSE), specifically 34 
responsible for breakdown of heparan sulfate (HS) in lysosomes and the extracellular matrix (ECM).  35 
Both enzymes are strongly implicated in disease processes: deficiency of GUSB is the basis of the 36 
autosomal recessive disease mucopolysaccharidosis type VII (MPSVII), also known as Sly syndrome1-37 
3, whilst HPSE overexpression is linked to a variety of pathologies including inflammation and cancer 38 
metastasis4,5. 39 
Although both GUSB and HPSE possess E-glucuronidase activity, these enzymes are dissimilar at the 40 
sequence level and fall under different families of the Carbohydrate Active enZymes (CAZy) 41 
classification scheme6: GH2 for GUSB and GH79 for HPSE.  Structurally, human GUSB is a large 42 
homotetrameric assembly, with each protomer comprising a (E/D)8 barrel domain, a jelly roll domain 43 
and an Ig constant chain like domain7.  In contrast, HPSE is a heterodimer comprised of 8 kDa and 50 44 
kDa subunit chains, which fold to produce a (E/D)8 barrel flanked by a smaller E-sandwich domain8.  45 
The mature HPSE heterodimer is formed by proteolytic removal of a 6 kDa linker peptide from a 46 
single chain proenzyme - proHPSE. 47 
Given the importance of E-glucuronidases in human health and disease, a facile method to visualize 48 
and quantitate their activity would be of great utility.  We have previously reported the 49 
development of activity based probes (ABPs) based upon the cyclophellitol aziridine scaffold, which 50 
can be used to specifically detect enzymatic activity for a range of glycosidases9-14.  These probes 51 
provide valuable tools to rapidly determine enzyme activities within their native physiological 52 
contexts. 53 
Herein, we unveil the synthesis of ABPs designed to selectively target and label retaining E-54 
glucuronidases. We demonstrate the utility of these probes in quantitating E-glucuronidase activity 55 
in a range of cell and tissue samples, via both fluorescence and chemical proteomics approaches.  56 
Unexpectedly, we find that a monosugar E-glucuronidase probe is sufficient to label not only exo-57 
acting GUSB, but also endo-acting HPSE, despite binding just one of multiple subsites within the 58 
HPSE active site cleft. Furthermore, the supposedly inactive proHPSE proenzyme is also labeled by 59 
ABPs, prompting us to investigate the nature of proHPSE  ?ŝŶĂĐƚŝǀĂƚŝŽŶ ?ďǇits 6 kDa linker, and how 60 
this structure relates to other GH79 enzymes. Our results demonstrate a wide ranging potential of E-61 
glucuronidase ABPs as biological and biomedical tool compounds, and highlight the general power of 62 
ABPs for driving the discovery of novel biological insights15. 63 
Results 64 
Glucuronidase specific inhibitor and probe design  65 
We have previously demonstrated cyclophellitol derived epoxides and aziridines  to be powerful 66 
mechanism based inhibitors for retaining E-glucosidases16, due to their ability to specifically label the 67 
enzyme catalytic nucleophile, in a conformation resembling the covalent intermediate of glycoside 68 
hydrolase reactions. (Fig. 1a, b)17. Inhibition is typically tolerant to functionalization at the ring 69 
nitrogen of cyclophellitol aziridines, allowing fluorophore or biotin tagging to create inhibitor probes 70 
which can label specific glycosidases within complex biological mixtures18. 71 
Conceptually, we envisioned that E-glucuronidase specific ABPs could be accessed from 72 
cyclophellitol by oxidation at the C6 equivalent position, to emulate the carboxylate of glucuronic 73 
acid (GlcUA).  ABPs 1ʹ4 are composed of such a E-glucuronide configured cyclophellitol aziridine, 74 
bearing a spacer from the aziridine nitrogen terminating in BODIPY-FL, a BODIPY-TMR analog, Cy5, or 75 
biotin respectively.  Alongside these functionalized ABPs we also prepared azide substituted ABP 5 76 
(the precursor of 1ʹ4), unsubstituted aziridine 6 and cyclophellitol-6-carboxylate 7. (Fig. 1c; 77 
structures of additional compounds 8ʹ16 used in this study are shown in Supplementary Results, 78 
Supplementary Fig. 1).   79 
GlcUA ABPs target E-glucuronidases in vitro and in situ  80 
To assess the potency of our E-glucuronidase ABPs in vitro, we first turned to the exo-acting GH79 E-81 
glucuronidase AcGH79 from Acidobacterium capsulatum, whose activity is readily followed using the 82 
fluorogenic substrate 4-methylumbelliferyl-glucuronic acid (4MU-GlcUA)19.  All compounds tested 83 
were effective inhibitors of AcGH79, with apparent IC50s in the low to sub nM range (Table 1 left 84 
panel).  Core AW ?ǁĂƌŚĞĂĚ ? 6 inhibited AcGH79 with apparent IC50 of ~5 nM.  This was potentiated 85 
by further functionalization: apparent IC50 of Cy5 substituted ABP 3 was ~1 nM, whilst 1, 2, 4 and 5 86 
were all sub-nanomolar inhibitors of AcGH79.  Apparent IC50 for epoxide 7 was ~34 nM, consistent 87 
with lower reactivity of the epoxide moiety compared to aziridines.   88 
Kinetic parameters for inhibition of AcGH79 were determined using a continuous assay, whereby 89 
substrate and inhibitor react with enzyme simultaneously (Supplementary Note 1)20, allowing us to 90 
derive a combined inhibition parameter ki/KI for all ABPs tested.  ki/KI values largely reflected the 91 
trend seen with IC50s, with the activity of core aziridine 6 potentiated by further functionalization, 92 
and epoxide 7 substantially less active than aziridines (Table 1 middle panel, Supplementary Fig. 2).   93 
Finally, we tested the ability of our probes to inhibit E-glucuronidases in live fibroblast cells.  In situ 94 
apparent IC50s were determined for ABPs 2 and 3 to be in the low PM range (~1.7 and ~1.8 PM 95 
respectively).  We were unable to determine in situ apparent IC50s for 1 or 4ʹ7, likely reflecting a 96 
limited ability of these compounds to permeate the cell membrane (Table 1 right panel). 97 
Fluorescent labeling of AcGH79 by ABP 1 was readily visualized after running on SDS-PAGE, and 98 
could be blocked by competition with 2ʹ7, 4MU-GlcUA, or iminosugar 8. Labeling also was abolished 99 
by SDS denaturation of protein, in line with a mechanism-based mode of action requiring 100 
catalytically competent enzyme (Supplementary Fig. 3a).    101 
To dissect the mechanistic mode of action of our probes, we obtained crystal structures of 5 in 102 
complex with wild type AcGH79, and an inactive AcGH79(E287Q) nucleophile mutant 103 
(Supplementary Fig. 3b, c).  Both complexes showed a single molecule of 5 bound within the active 104 
site of AcGH79, with no labeling of off-target residues.  In wild type AcGH79, reacted 5 was observed 105 
bound via C1 to the enzyme nucleophile (Glu287) in a 4C1 conformation, making identical non-106 
covalent contacts as previously observed for GlcUA or 2F-GlcUA19.  In the AcGH79(E287Q) mutant, 5 107 
occupied the same active site position, but was instead found to adopt a 4H3 conformation, due to 108 
restricted rotation across the C1-C7 bond imposed by the aziridine.  Notably, the 4H3 conformation 109 
observed for unreacted 5 is the same as that postulated for oxocarbenium-like transition states of 110 
retaining E-glycosidase substrates during hydrolysis (Supplementary Fig. 3d)21.  The high affinities of 111 
cyclophellitol derived ABPs for their target enzymes may thus be in part due to their conformational 112 
mimicry of this transition state22. 113 
ABP profiling reveals GUSB and HPSE as probe targets  114 
To determine the targets of retaining E-glucuronidase ABPs in complex biological samples, human 115 
splenic lysates (which we have previously shown to express a range of glycosidases10-12) were treated 116 
with one or more ABPs, resolved by SDS-PAGE, and labeled proteins visualized by fluorescent 117 
scanning (the typical ABP workflow is shown in Supplementary Fig. 4).   118 
Several fluorescent bands were observed in samples treated with Cy5 ABP 3 which were absent in a 119 
mock (DMSO) control, and which could be competed for by biotin ABP 4 (Fig. 2a).  Based on 120 
literature reports, we tentatively assigned the prominent double bands at ~78 ?80 kDa as full length 121 
and C-terminal truncated isoforms of GUSB23, and the lowest molecular weight band as the ~64 kDa 122 
isoform of GUSB24 ; these bands were also identified by an anti-GUSB western blot (Supplementary 123 
Fig. 5a).  A band at ~60 kDa did not correspond with any known glucuronidases but could be 124 
abrogated by pretreatment with E-glucosidase ABP 9, suggesting this was the lysosomal acid E-125 
glucosidase GBA, which is specifically labeled by 912.  Correspondingly, this ~60 kDa band was also 126 
absent in splenic lysates from patients with Gaucher disease, which is characterized by lack of GBA 127 
activity.   128 
To unambiguously establish the targets of our ABPs, we carried out a set of chemical proteomics 129 
experiments using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS).  130 
Lysates from normal or Gaucher spleens were incubated with biotin ABP 4, with or without 131 
pretreatment using 9.  Labeled proteins were then pulled down using streptavidin beads, and 132 
ƉƌŽĐĞƐƐĞĚƵƐŝŶŐĂƐƚĂŶĚĂƌĚƉƌŽƚĞŽŵŝĐƐǁŽƌŬĨůŽǁ ?ƵƚŝůŝǌŝŶŐďŽƚŚ ?ŝŶ-ŐĞů ?ĂŶĚ ?ŽŶ-ďĞĂĚ ?ĚŝŐĞƐƚ133 
protocols (Supplementary Fig. 4).  dŚĞ ?ŽŶ ďĞĂĚ ?digest protocol was also applied to human 134 
fibroblast lysates, in order to assess the efficacy of ABP pulldown in another tissue type.   135 
Proteomic profiling using the  ?ŝn-gel ? digest protocol identified GUSB as the predominant splenic 136 
protein labeled by 4, with particular enrichment in bands corresponding to those previously 137 
identified by 3 (Fig. 2b).  As with fluorescent labeling, we detected GBA at ~60 kDa, which was 138 
abrogated by pretreatment with 9 and reduced in Gaucher spleen.  ?In-ŐĞů ?ƉƌŽƚĞŽŵŝĐƌĞƐƵůƚƐǁĞƌĞ139 
largely mirrored by those from the  ?ŽŶďĞĂĚ ?ƉƌŽƚŽĐŽl, which showed GUSB to be the most abundant 140 
glycosidase after pulldown from spleen, and also highly enriched after pulldown from fibroblast 141 
(Supplementary Data Set 1).   Covalent modification of the GUSB nucleophile (Glu540) by 4 was 142 
directly characterized by MS/MS fragmentation of the 13 amino acid peptide containing this residue 143 
(Supplementary Fig. 5b).   144 
The high sensitivity of proteomic profiling enabled detection of two glycosidase enzymes in splenic 145 
lysates not observed by fluorescent labeling with 3: E-galactosidase GLB1, and endo E-glucuronidase 146 
HPSE.  Both enzymes were substantially less abundant in pull-down fractions compared to GUSB, as 147 
estimated by their exponentially modified protein abundance index (emPAI) scores (Supplementary 148 
Fig. 5c).  We theorized that GLB1 was likely a weak non-specific target of 4, as it showed the lowest 149 
emPAI of all detected glycosidases despite robust transcriptional expression reported in spleen 150 
(Supplementary Fig. 5d)25, and strong histochemical staining of E-galactosidase activity in 151 
mammalian splenic tissues26.  In contrast, HPSE is predicted to be poorly expressed in spleen by 152 
transcriptomics, yet showed a higher emPAI score than GLB1 after pull-down by 4.  These 153 
observations suggested HPSE was a bona fide target of our ABPs, despite the inability of the 154 
monosugar probes to make a full complement of interactions within the HPSE endo-acting substrate 155 
cleft, which normally accommodates at least a trisaccharide27.   156 
E-glucuronidase ABPs label endogenous HPSE and proHPSE 157 
Following the surprising discovery that splenic HPSE was labeled by 4, we re-examined fluorescent 158 
labeling of HPSE in cells and tissues expressing higher levels of HPSE. In the first instance, we induced 159 
HPSE overexpression in HEK293T cells, and probed harvested lysates at set intervals. Two plasmids 160 
were tested: pGEn1-HPSE, encoding for N-His-Strep-TEV tagged proHPSE, and pGEn2-HPSE, encoding 161 
for N-His-Avitag-eGFP-TEV tagged proHPSE; HEK293T cells subsequently process these proHPSE 162 
precursors to mature HPSE.   163 
Using 3, we tracked increasing expression of a band at ~50 kDa, corresponding to the mass of the 164 
large HPSE subunit, which contains the nucleophile Glu343 (Fig. 3a)28.  Unexpectedly, we also 165 
detected bands at ~75 kDa for pGEn1-HPSE and ~100 kDa for pGEn2-HPSE, corresponding to the 166 
masses of proHPSE chains expressed by these plasmids.  Western blotting using an anti-HPSE 167 
antibody confirmed these bands to be proHPSE, indicating that 3 also labeled the supposedly 168 
inactive proenzyme.  Initial comparison of band intensities from ABP labeling using 3 vs. western 169 
blotting suggested that 3 labeled mature HPSE with greater efficiency than it labeled proHPSE.  170 
However, the opposite trend was observed when using purified recombinant proHPSE 171 
(Supplementary Fig. 6a), suggesting that the majority of proHPSE overexpressed by HEK293T cells 172 
was likely inactive.   173 
HPSE maturation is thought to be mediated by the cysteine protease cathepsin L (CTSL), through 174 
multiple proteolytic cleavages of the 6 kDa linker peptide29. We tested the effect of CTSL inhibitors 175 
CAA022530 (10), Z-FY(tBu)-DMK31 (11) and leupeptin on proHPSE maturation in HEK293T cells by 176 
incubating cells transfected pGEn1-HPSE with CTSL inhibitors for 2 d and labeling lysates with 3.  In 177 
inhibitor treated cells, we observed modest but dose dependent accumulation of a band ~5 kDa 178 
below the principal proHPSE band, corresponding to loss of the unstructured N-His-Strep-TEV tag 179 
followed by blockade of further proteolysis, in line with the role of CTSL in HPSE maturation 180 
(Supplementary Fig. 6b).  However, accumulation of mature HPSE was still detected in the presence 181 
of all inhibitors tested, suggesting either incomplete CTSL inhibition, or the presence of non-182 
cathepsin mediated HPSE maturation pathways also utilized by HEK293T cells.   183 
We also tracked internalization and processing of proHPSE to mature HPSE in fibroblasts, a process 184 
which may be utilized by cancer cells to increase their own levels of HPSE: by capturing and 185 
internalizing extracellular proenzyme32.  Within 90 minutes of introducing proHPSE into culture 186 
medium, internalization and processing of HPSE by fibroblasts was detectable using 3 (Fig. 3b).  187 
These experiments demonstrate the ability of E-glucuronidase ABPs to detect and track key 188 
biological processes such as HPSE internalization and maturation. 189 
Lastly, we reattempted fluorescent labeling of endogenous HPSE in human tissues.  As splenic HPSE 190 
expression was below the fluorescent detection limit, we turned to platelets, which are known to 191 
contain high levels of mature HPSE33.  Using 3, we observed labeling of a band at ~50 kDa in platelet 192 
lysates corresponding to HPSE, in addition to the same GUSB bands previously detected in spleen 193 
(Fig. 3c). Comparison of fluorescence and western blotting intensities between platelet HPSE and a 194 
200 fmol recombinant standard suggested fluorescent sensitivity for recombinant HPSE to be in the 195 
fmol range, somewhat more sensitive than western blotting in our hands. Fluorescent HPSE 196 
detection in platelet lysates was slightly less sensitive, possibly due to the presence of competing 197 
protein targets or inactive HPSE in situ. 10 nM of 3 was sufficient to produce a detectable HPSE 198 
signal in platelets after 30 minutes (Supplementary Fig. 6c). Labeling of HPSE, but not GUSB, was 199 
also improved by the addition of NaCl (Supplementary Fig. 6d).  Optimum labeling of HPSE by 3 was 200 
achieved at pH 4.5 ?5.0, consistent with literature reports of its optimum pH for enzymatic activity34.  201 
In contrast, optimum pH for labeling GUSB was higher than expected at pH ~5.5 ?6.0 (Fig. 3d), 202 
compared to its reported optimum for activity at the lysosomal pH ~4.535. This unexpected pH of 203 
GUSB ABP labeling may be due to facile aziridine ring opening occurring independently of a 204 
protonated acid/base residue36.  However, optimum labeling of GUSB at a non-lysosomal pH 205 
presents its own serendipitous advantages, allowing both GUSB and HPSE to be analyzed either 206 
jointly or independently of each other through modulation of labeling pH. 207 
Competitive ABP labeling identifies HPSE specific inhibitors 208 
Because ABPs can detect a complete complement of enzymes in a cellular/environmental sample, 209 
competitive ABP labeling provides a powerful tool to assess inhibitor efficacy and specificity within a 210 
single experiment37.  We sought to establish whether GlcUA ABPs could be used for the assessment 211 
of enzyme specific inhibitors, by testing platelet labeling at pH 5.0 (where both GUSB and HPSE 212 
react) in the presence of a set of known inhibitors. 213 
In the presence of the monosaccharide-like E-glucuronidase inhibitor siastatin B38, both GUSB and 214 
HPSE labeling were abrogated in a dose-dependent manner, demonstrating the ability of this 215 
molecule to outcompete ABP binding in both endo- and exo- acting enzymes.  Using quantitated 216 
band intensities, IC50s for GUSB and HPSE labeling inhibition were measured to be ~3.3 PM and ~6.7 217 
PM respectively, indicating slightly greater affinity for GUSB by siastatin B (Fig. 4a). 218 
In contrast, HPSE labeling in platelets was selectively inhibited by competition with heparin (12, IC50 219 
~0.17 mg/mL, Fig. 4b), a large polysaccharide which cannot be accommodated by the exo- acting 220 
active site of GUSB.  Selective inhibition was also observed upon competition with HS (13), the 221 
substrate of HPSE, albeit with slightly lower potency (Fig. 4c, IC50 ~0.50 mg/mL).  Negligible 222 
inhibition was observed for N-Acetyl-O-desulfated heparin (14) (Supplementary Fig. 7a), highlighting 223 
the importance of sulfation for interactions between heparin/HS and HPSE.  A lower degree of 224 
sulfation in HS vs. heparin may partly account for its slightly weaker abrogation of ABP labeling39.   225 
We next tested labeling inhibition by GAGs with different linkages and sulfation patterns to heparin 226 
and HS.  Hyaluronic acid (15) and chondroitin sulfate (16) both showed no inhibition of either HPSE 227 
or GUSB labeling at concentrations sufficient for inhibition by heparin/HS (Supplementary Fig. 7b, c), 228 
highlighting the critical role of sugar linkage and sulfation in interactions between GAGs and HPSE.  229 
Taken together, these assays provide proof of principle that GlcUA ABPs are amenable for use in a 230 
competitive format, to assess inhibition of specific E-glucuronidases within a mixture of related 231 
activities.   232 
Structural basis of HPSE and proHPSE ABP labeling 233 
To investigate how efficient labeling of endo-acting HSPE was achieved by a monosugar ABP, we 234 
obtained crystal structures of both wild type and nucleophile mutant (E343Q) HPSE in complex with 235 
ABP 5.  Complexes of HPSE with 5 were similar to those obtained with AcGH79, showing a single 236 
molecule of probe occupying the  ?1 subsite of the HPSE substrate binding cleft (nomenclature 237 
according to Ref. 40) in reacted 4C1 (wild type) or unreacted 
4
H3 (mutant) conformations 238 
(Supplementary Fig. 8a).  The network of interactions made to the probe was highly similar between 239 
AcGH79 and HPSE, with the primary difference being a lack of interaction by HPSE to O4 of the 240 
probe, due to extension of its natural HS substrate towards this position (Supplementary Fig. 8b).  A 241 
 ?1 subsite C6 carboxylate recognition motif, comprising 3 H-bonds from a tyrosine and two 242 
consecutive backbone amides, is highly conserved in GH79 E-glucuronidases (Tyr 334, Gln293-243 
Gly294 in AcGH79; Tyr391, Gly349-Gly350 in HPSE; Tyr 302, Gly261-Gly262 in the recently 244 
characterized heparanase from Burkholderia pseudomallei)41.  This strong network of H-bonds to C6 245 
carboxylate likely offsets the absence of only a single H-bond to O4 of the ABP in HPSE compared to 246 
AcGH79, thus rationalizing robust labeling of HPSE by a monosaccharide probe that  only occupies a 247 
single subsite within its extensive binding cleft.  Additional binding affinity may also derive from the 248 
transition state like 4H3 conformation adopted by unreacted ABPs.   249 
We next sought to solve the structure of proHPSE, in order to characterize the basis of its 250 
 ?ŝŶĂĐƚŝǀĂƚŝŽŶ ?ďǇthe 6 kDa linker peptide, and to determine how E-glucuronidase ABPs are able to 251 
circumvent this.  Herein, we report the first crystal structure of proHPSE in both apo and ABP 252 
complexed forms, which together with previously reported HPSE structures completes a structural 253 
characterization of the HPSE maturation process.   254 
The proHPSE structure was similar to that of mature HPSE (RMSD: 0.52 Å over 451 CD), with the 255 
same (E/D)8 and E-sheet domains clearly discernible.  The 6 kDa linker (110-157) forms a large helical 256 
domain which sits directly  ?above ? the active site cleft, blocking access to the bulky HS substrates of 257 
HPSE. The final loop of the linker leading into the 50 kDa subunit (His155-Lys159) is substantially 258 
more disordered than the rest of the protein, as evidenced by higher B-factors for these residues in 259 
the crystallographic model (Supplementary Fig. 9a, b).  Mutation studies have established Tyr156 of 260 
the proHPSE linker to be critical for recognition by CTSL in the first step of HPSE maturation42.  261 
Disorder of the His155-Lys159 loop allows for unencumbered CTSL access to Tyr156 without 262 
disrupting preexisting secondary structures, consistent with the important role of Tyr156 in HPSE 263 
maturation. 264 
Unexpectedly, steric blockage by the linker peptide was found to be incomplete in proHPSE, leaving 265 
Ă ?binding ƉŽĐŬĞƚ ?on the protein surface containing exposed catalytic nucleophile and acid/base 266 
residues, similar to the exo-acting active site of AcGH79 (Fig. 5a).  When compared in a sequence 267 
alignment, the proHPSE linker corresponds to a loop in AcGH79, ǁŚŝĐŚĨŽƌŵƐƚŚĞ ?ƌĞĂƌ ?ĨĂĐĞŽĨŝƚƐ268 
active site pocket, suggesting that whilst this sequence has expanded in the human enzyme, 269 
proHPSE still retains some structural characteristics reminiscent of a GH79 exo-glycosidase 270 
(Supplementary Fig. 8c).  ABP 5 was found to bind ƚŽƚŚŝƐƉƌŽ,W^ ?ĂĐƚŝǀĞ-site ƉŽĐŬĞƚ ?ŝŶĂ271 
configuration identical to that observed for HPSE.  The O4 proximal position, vacant in HPSE, was 272 
occupied by His155 in proHPSE, contributed by the linker, which blocks off extension towards this 273 
position by HS substrates (Fig. 5b, c).  The disordered proHPSE His155-Lys159 loop was slightly 274 
displaced upon binding 5 (~1.54 Å for Tyr156 CD), due to steric clashes with the bound ABP 275 
(Supplementary Fig. 9c). 276 
As with mature HPSE, proHPSE was inactive against the artificial fluorogenic substrate 4MU-GlcUA, 277 
indicating it does not possess any additional exo-glucuronidase activity against this substrate which 278 
is lost upon maturation (Supplementary Fig. 8d).  To assess the accessibility of the proHPSE  ?pocket ? 279 
compared to mature HPSE, we conducted competitive ABP experiments against recombinant 280 
proHPSE and HPSE using 3.  As with platelets, siastatin B inhibited ABP labeling of both pro- and 281 
mature HPSE (Supplementary Fig. 10a), indicating it could efficiently occupy the  ?binding pocket ? of 282 
proHPSE as well as HPSE.  In contrast, heparin only inhibited labeling of HPSE, albeit with lower 283 
efficacy than seen in platelets, due to more facile labeling of the recombinant enzyme.  284 
Unexpectedly, proHPSE labeling was slightly increased at moderate heparin concentrations 285 
(Supplementary Fig. 10b).  Finally, we tested the ability of GlcUA to inhibit labeling of HPSE and 286 
proHPSE.  No substantial inhibition of either proHPSE or HPSE labeling was observed at up to 20 mM 287 
GlcUA (Supplementary Fig. 10c), suggesting that GlcUA cannot occupy the active site of (pro)HPSE 288 
with sufficient affinity to prevent binding and reactivity of an ABP.  Further subsite interactions may 289 
be required for binding of simple glucuronides to (pro)HPSE. 290 
It has previously been demonstrated that proHPSE uptake by cells is a HS dependent process, and 291 
can be disrupted by addition of exogenous heparin43.  To investigate  possible roles for the proHPSE 292 
 ?ďŝŶĚŝŶŐƉŽĐŬĞƚ ?ŝŶ proHPSE uptake and maturation, we prelabeled recombinant proHPSE with  293 
either untagged ABP 6, fluorescent ABPs 1 or 3, or a mock DMSO control, and examined its uptake 294 
by fibroblasts at 90 or 180 min.  In all cases, prelabeled proHPSEs were taken up and processed to 295 
mature HPSE, as evidenced by western blot and fluorescence of internalized 1 or 3 (Supplementary 296 
Fig. 11).  These data indicate ƚŚĂƚƚŚĞƉƌŽ,W^ ?ƉŽĐŬĞƚ ?ĚŽĞƐŶŽƚƉĂƌƚŝĐŝƉĂƚĞŝŶƚŚĞ,^ŝŶƚĞƌĂĐƚŝŽŶƐ297 
involved in cellular uptake, and that occupation of the proHPSE  ?ƉŽĐŬĞƚ ?does not inhibit HPSE 298 
maturation.   299 
Discussion 300 
The important role of E-glucuronidases in human biology is highlighted by the pathologies 301 
associated with aberrant expression of these enzymes.  Lack of GUSB activity leads to accumulation 302 
of glucuronide-containing GAGs within lysosomes in MPSVII (Sly Syndrome).  Conversely, 303 
overexpression of HPSE leads to aberrant breakdown of HS in the ECM, causing increased cancer 304 
growth and metastasis.  Accurate tracking of E-glucuronidase activities is an essential prerequisite 305 
for fully understanding their role in both physiological and disease states.  306 
Here we have reported the design and application of novel E-glucuronidase configured ABPs, and 307 
demonstrated their broad utility for interrogating activities of these enzymes.  We show that ABP 308 
profiling is a viable method to assay E-glucuronidase activity in a variety of samples, ranging from 309 
recombinant proteins, to complex cell, tissue and organ lysates. Fluorescent labeling provides a 310 
facile method for probing E-glucuronidases in tissues with sufficient expression, allowing for tracking 311 
of processes such as proenzyme uptake and processing, and how these are affected by biological or 312 
pharmacological perturbation. In tissues with lower enzyme abundance, we have demonstrated 313 
detection of E-glucuronidases using a proteomic approach, which is also applicable for the discovery 314 
of previously uncharacterized E-glucuronidase activities in biological samples.   315 
Use of ABPs provides several advantages over more traditional methods to quantitate glycoside 316 
hydrolase activities.  Compared to techniques such as western blotting, ABPs specifically detect 317 
active enzymes, rather than an entire protein complement which may include misfolded or inactive 318 
isoforms.  Whilst fluorometric or colorimetric assays also provide assessments of enzyme activity, 319 
they cannot distinguish between overlapping activities in complex mixtures, which arise from several 320 
enzymes or enzyme isoforms active on the same substrate.  Indeed, many carbohydrate processing 321 
enzymes are processed from precursors into one or more isoforms with differing activities23,28,44,45.  322 
ABP profiling allows for multiple activities to be visualized and their responses to perturbation or 323 
inhibition to be individually assessed in situ.   324 
Many endo-glycosidases such as HPSE are inactive in traditional activity assays, necessitating the use 325 
of expensive specialized substrates and/or cumbersome assay procedures to follow their activities.  326 
The discovery that aziridine ABPs label HPSE paves the way for more rapid and practicable methods 327 
to assess the activity of this enzyme, and may inspire development of probes to assay other endo-328 
glycosidases.  Whilst this current generation of E-glucuronidase ABPs shows some off-target effects 329 
against GBA and GLB1, limiting their use in diagnostic applications, further optimization based upon 330 
the crystal structures of HPSE (and proHPSE) may lead to improved probes with increased potency 331 
and specificity.  Optimization efforts will be aided by the use of competitive ABP techniques, which 332 
we have demonstrated to be a viable method for assessing selective inhibitors of individual E-333 
glucuronidases.   334 
ABPs also provide powerful tools for characterization of novel enzyme activities, which may escape 335 
detection in traditional biochemical experiments. The use of an ABP driven approach in this study 336 
lead us to the surprising observation that the HPSE precursor proHPSE is in principle catalytically 337 
competent, an entirely unanticipated outcome based on previous studies.  We have reported the 338 
first structural views of proHPSE, illustrating how its 6 kDa linker restricts access to the active site 339 
cleft for HS substrates.  This linker does not entirely block access to the catalytic residues of 340 
proHPSE, but instead contributes to the formation of an exo-glycosidase like  ?ďŝŶĚŝŶŐpocket ?, which 341 
can accommodate smaller molecules.  It remains to be determined whether this proHPSE  ?pŽĐŬĞƚ ?ŝƐ342 
simply a structural relic from evolutionary expansion of an ancestral GH79 active site loop, or if there 343 
are bona fide endogenous substrates which are hydrolyzed by proHPSE. 344 
In conclusion, we have presented a set of ABPs for functional interrogation of E-glucuronidases in 345 
their native contexts.  The application of ABP methodology to carbohydrate processing enzymes 346 
provides a powerful set of tools to study the activity of these key enzymes, and will contribute 347 
towards our understanding of fundamental processes in glycobiology.   348 
Accession codes 349 
Coordinates and structure factors have been deposited in the Protein Data Bank under accession 350 
codes 5G0Q (AcGH79(wt)-5 complex), 5L77 (AcGH79(E287Q)-5 complex), 5L9Y (HPSE(wt)-5 351 
complex), 5L9Z (HPSE(E343Q)-5 complex), 5LA4 (apo proHPSE), 5LA7 (proHPSE-5 complex). 352 
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  482 
Figure 1 ŽŶĐĞƉƚĂŶĚĚĞƐŝŐŶŽĨɴ-glucuronidase targeting ABPs. a Generalized schematic of double-483 
ĚŝƐƉůĂĐĞŵĞŶƚ ŵĞĐŚĂŶŝƐŵ ĞŵƉůŽǇĞĚ ďǇ ƌĞƚĂŝŶŝŶŐ ɴ-glycosidases. b Mechanism based inhibition by 484 
cyclophellitol derived ABPs. c Structures of cyclophellitol, cycloƉŚĞůůŝƚŽů ĂǌŝƌŝĚŝŶĞ ? ĂŶĚ ɴ-485 
glucuronidase specific ABPs used in this study. Numbering of atomic positions is shown on 486 
cyclophellitol.   487 
Figure 2 ABP labeling of retaining E-glucuronidases in human spleen lysates. a Three isoforms of 488 
GUSB are fluorescently labeled by Cy5 ABP 3 in human wild type spleen, along with off target 489 
labeling of the E-glucosidase GBA. Labeling of these proteins by 3 can be competed for by biotin ABP 490 
4.  GBA labeling in wild type spleen is also specifically competed for by 9, and is absent in lysates 491 
from Gaucher spleen. b Silver stained SDS-PAGE gel of proteins captured from human wild type 492 
spleen by labeling with 4 (with or without competition by 9) followed by streptavidin pulldown. 493 
Glycosidase enzymes identified in each gel band by proteomic profiling are listed. Full proteomics 494 
datasets for proteins identified by ABP pulldowns are available in Supplementary Data Set 1. 495 
Figure 3 Human HPSE is readily visualized by fluorescent E-glucuronidase ABPs. a Induced 496 
overexpression of HPSE and proHPSE in HEK293T cells  can be tracked by ABP 3. Fluorescent labeling 497 
by 3 correlates with bands from western blotting using an anti-HPSE antibody. b ABP tracking of 498 
uptake and processing of proHPSE to HPSE by fibroblast cells. c Endogenous HPSE in human platelets 499 
can be labeled by 3, along with the same GUSB bands as observed in spleen. d pH dependence of 500 
HPSE and GUSB labeling in platelet lysates, demonstrating how general or specific enzyme labeling 501 
can be achieved by modulating pH.   502 
Figure 4 General and endo-specific inhibition of E-glucuronidases assessed by competitive ABP 503 
profiling. a Monosugar like E-glucuronidase inhibitor siastatin B can be accommodated exo- and 504 
endo- acting E-glucuronidase active sites, and competes out ABP 3 labeling of both GUSB and HPSE. 505 
b Polysaccharide heparin (12) only inhibits ABP labeling of HPSE, due to its inability to interact with 506 
the exo- configured active site of GUSB. c Selective HPSE inhibition is also achieved by heparan 507 
sulfate (13). Competitive ABP gels shown are representative of three technical replicates. Plots are 508 
mean values r s.d. (N=3) for quantitated HPSE and GUSB fluorescent band intensities, normalized to 509 
band intensities in the no inhibitor control lane. For all plots, quantitated GUSB fluorescence is a sum 510 
of the three assigned bands. n.d.: not determined.   511 
Figure 5 3-dimensional structure of proHPSE, and its active site interactions with ABP 5. a Ribbon 512 
and surface diagram of proHPSE, demonstrating steric blockage of the HPSE binding cleft by the 6 513 
ŬĂůŝŶŬĞƌ ?ŶĞǆƉŽƐĞĚ ?ƉŽĐŬĞƚ ?ŝŶƉƌŽ,W^ĐĂŶƐƚŝůůinteract with small molecules such as 5 514 
(highlighted pink for clarity).  b ABP 5 in complex with proHPSE within its  ?binding ƉŽĐŬĞƚ ? ?dŚĞK ?515 
position, where HS substrates would extend in mature HPSE, is blocked by His155, contributed by 516 
the linker (colored in green). Density is REFMAC maximum-likelihood/VA ǁĞŝŐŚƚĞĚ ?&ŽA?&ĐĐŽŶƚŽƵƌĞĚ517 
to 0.38 electrons/Å3. c Schematic of H-bonding interactions between reacted 5 and proHPSE active 518 
site residues. Interactions are identical to those observed for the mature enzyme (Supplementary 519 
Fig. 8a, b), except for His155 proximal to O4 of the probe. (nuc.: nucleophile; a/b: acid base). 520 
 521 
Table 1 Apparent IC50 values for in vitro and in situ ŝŶŚŝďŝƚŝŽŶŽĨɴ-glucuronidase activity by ABPs, 522 
and kinetic parameters for inhibition of AcGH79 by ABPs.  Data are mean values r s.d. (N=3) from 523 
three biological replicates. 524 
Compound In vitro AcGH79 
apparent IC50 (nM) 
Kinetic Parameters (AcGH79) 
ki/KI (PMʹ1minʹ1) 
In situ fibroblast 
apparent IC50 (PM) 
1 0.6r0.2 25.0r0.7 >15  
2 0.8r0.2 18.2r0.9 1.7r0.6 
3 1.1r0.1 14.0r0.8 1.8r0.4 
4 0.4r0.02 5.5r0.2 >15 
5 0.1r0.01 18.8r0.7 >15 
6 4.6r0.03 3.5r0.2 >15 
7 33.4r3.1 0.49r0.05 >15 
  525 
Methods 526 
Chemical probes and inhibitors 527 
4MU-GlcUA, Leupeptin, Siastatin B, Hyaluronic Acid (15) and Chondroitin Sulfate (16) were obtained 528 
from Sigma Aldrich.  CTSL inhibitors CAA0225 (10) and Z-FY(tBu)-DMK (11) were obtained from 529 
Merck. Heparin (12) and Heparan Sulfate (13) were obtained from Iduron.  N-Acetyl-O-desulfated 530 
Heparin (14) was obtained from Dextra. Cyclophellitol, cyclophellitol aziridine46 and ABP 910 were 531 
synthesized according to described procedures. Syntheses of compounds 1ʹ8 are described in 532 
Supplementary Note 2. 533 
Tissue and cell samples 534 
Gaucher patients were diagnosed on the basis of reduced GBA activity and demonstration of an 535 
abnormal genotype. Spleens from a normal subject and a patient suffering from type 1 Gaucher 536 
disease were collected after splenectomy and frozen at  ?80 qC until use.  Platelets were collected 537 
from healthy donors, using EDTA as the anti-coagulant. Platelet rich plasma (PRP) was prepared by 538 
centrifugation at 100 g for 20 min at 22 qC to remove red and white blood cells.  Platelets were 539 
isolated from PRP by centrifugation at 220 g for 10 min at 22 qC, and frozen at  ?80 qC until use.  540 
Approval for tissue collection was obtained from the Academisch Medisch Centrum (AMC) and 541 
University of York medical ethics committees.  Informed consent was obtained from all donors.   542 
Primary human fibroblasts (CC-2511) were obtained from Lonza.  HEK293T cells (ATCC-CRL-3216) 543 
were obtained from the American Type Culture Collection (ATCC).  Sf21 and High Five cells for 544 
protein production were obtained from Invitrogen.  Cells were used as obtained from the supplier 545 
without further authentication.  All cells used tested negative for mycoplasma contamination.    546 
All tissue lysates were prepared in KPI buffer (25 mM potassium phosphate [pH 6.5], supplemented 547 
with 1 u cOmplete protease inhibitor cocktail (Roche)).  Cells/tissues were homogenized with a silent 548 
crusher S equipped with a type 7 F/S head (30,000 rpm, 3 u 7 sec) on ice.  Lysate protein 549 
concentrations were determined with a Qubit 2.0 Fluorometer (Invitrogen) or Bradford assay using 550 
BSA as a standard. Lysates were stored in aliquots at  ?80 qC until use. 551 
Recombinant protein cloning, expression and purification 552 
AcGH79 553 
The coding sequence of AcGH79 with an N-terminal 6uHis tag was cloned into pET28a (Novagen), 554 
which was used to transform E. coli BL21-Gold(DE3) (Agilent).  Transformants were grown at 37 qC in 555 
LB media containing 50 Pg/mL kanamycin to an OD600 of 0.8, induced by addition of 1 mM isopropyl 556 
E-D-1-thiogalactopyranoside, and protein production carried out out at 25 qC for 12 h.  Harvested 557 
cells were resuspended in 50 mL AcGH79 HisTrap buffer A (20 mM HEPES [pH 7.0], 200 mM NaCl, 5 558 
mM imidazole), lysed by sonication, and lysate clarified by centrifugation at 12000 g.  Supernatant 559 
containing AcGH79 was filtered before loading onto a HisTrap 5 mL FF crude column (GE Healthcare) 560 
pre-equilibrated with AcGH79 HisTrap buffer A. The loaded HisTrap column was washed with 10 561 
column volumes (CV) of AcGH79 HisTrap buffer A, before eluting with AcGH79 HisTrap buffer B (20 562 
mM HEPES [pH 7.0], 200 mM NaCl, 400 mM imidazole) over a 20 CV linear gradient.  563 
Fractions containing AcGH79 were pooled, concentrated using a 30 kDa cutoff Vivaspin concentrator 564 
(GE Healthcare) and further purified by size exclusion chromatography (SEC) using a Superdex 75 565 
16/600 column (GE Healthcare) in AcGH79 SEC buffer (20 mM HEPES [pH 7.0], 200 mM NaCl). 566 
Fractions containing AcGH79 were pooled and concentrated using a 30 kDa Vivaspin concentrator to 567 
a final concentration of 14.5 mg/mL, and flash frozen for use in further experiments. 568 
E287Q mutagenesis was carried out using a PCR based method47.  Mutant protein was purified using 569 
the same protocol as for wild type protein. Mutagenesis primers are listed in Supplementary Table 570 
2. 571 
Mature HPSE 572 
Mature HPSE cloning, expression, purification was carried out as previously described8.  573 
E343Q mutagenesis was carried out using a PCR based method.  Mutant protein was purified using 574 
the same protocol as for wild type protein. Mutagenesis primers are listed in Supplementary Table 575 
2. 576 
proHPSE 577 
Insect cells are unable to process proHPSE to mature HPSE, allowing the former to be isolated 578 
following expression.  cDNA encoding for proHPSE, minus the first 35 amino acid codons comprising 579 
ƚŚĞŶĂƚŝǀĞƐŝŐŶĂůƐĞƋƵĞŶĐĞ ?ǁĂƐĐůŽŶĞĚďĞŚŝŶĚĂ ? ?ŚŽŶĞǇďĞĞŵĞůůŝƚŝŶƐŝŐŶĂůƐĞƋƵĞŶĐĞ ? ?uHis tag, 580 
and TEV cleavage site, into the pOMNIBac plasmid (Geneva Biotech) using SLIC48.  pOMNIBac-581 
proHPSE was used to generate recombinant bacmid using the Tn7 transposition method in 582 
DH10EMBacY cells49 (Geneva Biotech). Baculovirus preparation and protein expression was carried 583 
out as previously described for mature HPSE.   584 
For purification, 3 L of conditioned media was cleared of cells by centrifugation at 400 g for 15 min at 585 
4 qC, followed by further clearing of debris by centrifugation at 4000 g for 60 min at 4 qC. DTT (1 586 
mM) and AEBSF (0.1 mM) were added to cleared media, which was loaded onto a HiTrap Sepharose 587 
SP FF 5 mL column (GE healthcare) pre-equilibrated in IEX buffer A (20 mM HEPES [pH 7.4], 100 mM 588 
NaCl, 1 mM DTT).  The loaded SP FF column was washed with 10 CV of IEX buffer A, and eluted with 589 
a linear gradient over 30 CV using IEX buffer B (20 mM HEPES [pH 7.4], 1.5 mM NaCl, 1 mM DTT). 590 
proHPSE containing fractions were pooled and diluted 10 fold into proHPSE HisTrap buffer A (20 mM 591 
HEPES [pH 7.4], 500 mM NaCl, 20 mM Imidazole, 1 mM DTT), before loading onto a HisTrap 5 mL FF 592 
crude column pre-equilibrated in proHPSE HisTrap buffer A. The loaded HisTrap column was washed 593 
with 10 CV HisTrap buffer A, and eluted with a linear gradient over 20 CV using proHPSE HisTrap 594 
buffer B (20 mM HEPES [pH 7.4], 500 mM NaCl, 1 M Imidazole, 1 mM DTT). proHPSE containing 595 
fractions were pooled and concentrated to ~2 mL using a 30 kDa cutoff Vivaspin concentrator, and 596 
treated with 5 PL EndoH (NEB) and 5 PL AcTEV protease (Invitrogen) for >72 h. Digested protein was 597 
purified by SEC using a Superdex S75 16/600 column in proHPSE SEC buffer (20 mM HEPES [pH 7.4], 598 
200 mM NaCl, 1 mM DTT).  proHPSE containing fractions were concentrated to 10 mg/mL using a 30 599 
kDa Vivaspin concentrator, exchanged into IEX buffer A via at least 3 rounds of 600 
dilution/reconcentration, and flash frozen for use in further experiments.     601 
 602 
Overexpression of HPSE in HEK293T cells 603 
pGEn1-HPSE and pGEn2-HPSE plasmids were obtained from the DNASU repository50. HEK293T cells 604 
were grown in DMEM media supplemented with 10% newborn calf serum (NBCS; Sigma) and 1% 605 
penicillin/streptomycin (Sigma). 20 Pg DNA was transfected into HEK293T cells at ~80% confluence, 606 
using linear PEI at a ratio of 3:1 (PEI:DNA). At relevant timepoints cells were washed with PBS, 607 
harvested into KPI buffer using a cell scraper, and pelleted by centrifugation at 200 g for 5 min at 4 608 
qC. Cell pellets were frozen at  ?80 qC prior to use.   609 
For CTSL inhibition experiments, transfections were carried out as above, except media was 610 
exchanged 7 h post transfection for DMEM supplemented with CTSL inhibitor or vehicle only control 611 
(0.05% v/v EtOH).  612 
proHPSE fibroblast uptake experiment 613 
Primary human fibroblasts were grown in DMEM/F12 media supplemented with 10% NBCS and 1% 614 
penicillin/streptomycin. Cells at 80% confluence were washed with PBS, before exchanging into 615 
DMEM/F12 media supplemented with proHPSE to 10 Pg/mL final concentration.  At relevant 616 
timepoints, cells were washed with ice cold PBS twice, harvested into KPI buffer using a cell scraper, 617 
and pelleted by centrifugation at 200 g for 5 min at 4 qC.  Cell pellets were stored at  ?80 qC prior to 618 
use. 619 
For uptake experiments with prelabeled proHPSEs, prelabeling was carried out in McIlvaine 620 
citrate/phosphate buffer [pH 5.0], 300 mM NaCl in 200 PL volume, using 50 PM proHPSE and 200 621 
PM ABP.  Reactions were incubated for 1 h for 37 qC, then excess ABP removed by desalting using a 622 
40 kDa MWCO Zeba spin column (Thermo).   Extent of prelabeling by 1 and 3 was quantified by 623 
comparison of protein and fluorophore UV/Vis absorption values.  Extent of prelabeling by 6 was 624 
estimated by testing residual reactivity to 3 (Supplementary Fig. 11b). 625 
Enzyme activity and inhibition assays 626 
Recombinant AcGH79 enzyme activity was assayed using 1.67 ng protein in 150 mM McIlvaine buffer 627 
[pH 5.0]. To determine apparent IC50 values, 25 PL AcGH79 was preincubated with a range of 628 
inhibitor dilutions for 30 min at 37 qC, followed by addition of 100 PL 4MU-GlcUA solution to give 629 
final concentrations of 260 pM AcGH79 and 2.5 mM 4MUGlcUA.  Reactions were carried out for 30 630 
min at 37 qC, quenched with 200 PL of 1 M NaOH-glycine [pH 10.3], and 4-MU fluorescence 631 
measured using a LS55 Fluorometer (Perkin Elmer) at Oex 366 nm andOem 445 nm. Apparent IC50 632 
values were determined in Prism (GraphPad) using a one phase decay function.  633 
Kinetic parameters for inhibition of AcGH79 were determined using a continuous method 634 
(Supplementary Note 1; also Ref. 20).  AcGH79 was added to pre-warmed mixtures of 4MU-GlcUA 635 
and ABP, to give final concentrations of 260 pM AcGH79 and 2.5 mM 4MU-GlcUA in a final reaction 636 
volume of 125 PL.  Reactions were incubated at 37qC.  At set timepoints, aliquots of reaction mixture 637 
were transferred to 96-well microplates (Greiner), quenched with 1 M NaOH-glycine [pH 10.3], and 638 
4MU fluorescence measured immediately using a LS-55 Fluorometer. The apparent rate of 639 
inactivation (kobs) was calculated for each ABP concentration by fitting with the exponential function 640 
[4MU]=A*(1-e^( ?kobs*t)).  The resulting plot of kobs vs. [ABP] was fitted using a linear function, which 641 
gives the combined apparent inhibition parameter ki/<͛I as the gradient.  ki/KI was derived from ki/<͛I 642 
by correcting for the presence of competing 4MU-GlcUA substrate, using the relationship 643 
<͛I=KI(1+[S]/KM), where [S] = 2.5 mM and KM = 18.2 PM.  All fittings were carried out using Prism. 644 
In situ fibroblast IC50s were determined by incubating human fibroblast cells with a range of 645 
inhibitor dilutions for 2 hours, followed by 3 u washing with PBS and harvesting into KPI buffer 646 
supplemented with 0.1% Triton X-100.  Harvested cells were pelleted by centrifugation at 200 g for 5 647 
min at 4 qC, and pellets stored at  ?80 qC prior to use.  Enzymatic reactions and apparent IC50 648 
calculations were performed as described for the in vitro IC50 determination experiments, but with 649 
5 Pg of total lysate protein per reaction.   650 
Fluorescent labeling 651 
Initial abeling reactions were carried out in McIlvaine buffer [pH 5.0], except for pH range 652 
experiments, which were carried out in McIlvaine buffer at the stated pHs. Typically 200 fmol 653 
recombinant protein was used for labeling AcGH79, HPSE and proHPSE (20 nM in 10 PL final reaction 654 
volume). 20 Pg total protein was used for labeling cell/tissue lysates, except for HEK293T 655 
overexpression experiments, where 10 Pg total protein was used. Unless otherwise specified, 656 
labeling reactions were carried out by incubation with 100 nM fluorescent ABP in a reaction volume 657 
of 10 PL for 1 h at 37 qC. Gels were scanned for ABP-emitted fluorescence using a Bio-Rad ChemiDoc 658 
MP imager with ƚŚĞƐĞƚƚŝŶŐƐ PǇ ? ?ʄEX  ? ? ?Ŷŵ ?ďĂŶĚƉĂƐƐ ? ?Ŷŵ ?ʄEM 530 nm, bandpass 28 nm) for 1, 659 
Ǉ ? ?ʄEX 530 nm, bandpĂƐƐ ? ?Ŷŵ ?ʄEM 605 nm, bandpass 50 nm) for 2 ?ĂŶĚǇ ? ?ʄEX 625 nm, 660 
ďĂŶĚƉĂƐƐ ? ?Ŷŵ ?ʄEM 695 nm, bandpass 55 nm) for 3.   661 
For labeling rate experiments with pro- and mature HPSE, reactions were carried out as above, 662 
except 2 pmol recombinant protein was incubated with an equimolar amount of 3 at 37 qC.  At 663 
specified timepoints, aliquots were removed from the reaction and denatured by boiling in Laemmli 664 
buffer.  Denatured samples were stored on ice until all timepoints were collected, and run together 665 
on SDS-PAGE.   666 
For competition experiments, optimized labeling reactions were carried out in McIlvaine buffer [pH 667 
5.0], 300 mM NaCl.  Protein samples were preincubated with inhibitor for 60 min at 37 qC prior to 668 
addition of 100 nM 3 for labeling.  Platelet lysates were labeled at 37 qC for 1 h, recombinant 669 
proteins were labeled at 37 qC for 30 min.  Following labeling, samples were denatured by boiling 670 
with Laemmli buffer for 5 min, and resolved by SDS-PAGE.  Gels used for quantitation were scanned 671 
using a laser based Bio-Rad FX molecular imager, using the ʄEX 635 nm external laser and 690BP 672 
emission filter.  Images were analyzed using Quantity One (Bio-Rad).  Full-length images of all 673 
fluorescent gels used in this study can be found in Supplementary Fig. 12. 674 
Chemical proteomics 675 
3 mg total protein from human wild type spleen, Gaucher spleen lysate, or human fibroblast lysate 676 
was incubated with either 10 PM 4, 10 PM 9 for 30 min followed by 10 PM 4, or a vehicle only 677 
control (0.1% DMSO).  All labeling reactions were carried out for 30 min at 37 qC in 500 PL McIlvaine 678 
buffer [pH 5.0], before denaturation by addition of 125 PL 10% SDS and boiling for 5 min. Samples 679 
were prepared for pull-down with streptavidin coupled DynaBeads (Invitrogen) as described 680 
previously51.  Following pull-down the samples were divided: 1/3 for in-gel digest and 2/3 for on-681 
bead digest. In-gel digest samples were eluted by boiling beads at 100 qC in 30 PL Laemmli buffer. 682 
Eluted proteins were separated by SDS-PAGE, and visualized by silver staining using the SilverQuest 683 
kit (Invitrogen). Bands were excised by scalpel and treated with gel digestion buffer (10 mM 684 
NH4HCO3, 5% ACN, 1mM CaCl2, 10 ng/PL trypsin) at 37 qC overnight.  The resulting trypsin-digested 685 
peptides were desalted using stage tips, followed by evaporation of ACN and resuspension into 70 686 
PL sample solution (95:3:0.1 H2O:ACN:TFA) for LC-MS analysis.  Samples were analyzed with a 2h 687 
gradient of 5 ?25% ACN on a nano-LC, hyphenated to an LTQ-Orbitrap.  Peptides were identified via 688 
the Mascot protein search engine.   689 
On bead digest samples were treated with trypsin digestion buffer (100 mM Tris [pH 7.8], 100 mM 690 
NaCl, 1 mM CaCl2, 2% ACN and 10 ng/PL trypsin) at 37 qC overnight with shaking. Trypsin digested 691 
peptides were desalted using stage tips, and analyzed as above. For identification of GUSB active-site 692 
peptides, trypsin digested beads were further treated with endoproteinase Glu-C digestion buffer 693 
(100 ng/PL Glu-C in PBS) at 37 qC overnight with shaking.  Digested peptides were desalted and 694 
analyzed as above. 695 
Peptide identification data were stringently filtered at a false discovery rate (FDR) of 1% and an 696 
MS/MS assignment Mascot score >40.  Full proteomics data are available in Supplementary Data Set 697 
1.  The data presented in Supplementary Data Set 1 show: the ranking of the proteins by the protein 698 
score, the UniProt accession number, trivial name of the protein, protein score, protein mass 699 
predicted from the RNA sequence, the amino acid coverage of the protein achieved by MS/MS 700 
sequencing, the query number of the peptide in the LC/MS run, the experimentally determined m/z 701 
of the peptide, the measured molecular weight, the charge state z, the predicted molecular weight, 702 
the delta accuracy between predicted and experimentally determined mass, the MS/MS assignment 703 
Mascot score, the expectancy value, peptide sequence and emPAI value (which gives an 704 
approximate relative estimation of peptide abundance). Full proteomics data are available in 705 
Supplementary Data Set 1. 706 
Western blotting  707 
Proteins resolved by SDS-PAGE were transferred to a PVDF membrane using a Trans-Blot Turbo 708 
system (BioRad).  Membranes were blocked in 5% BSA for 1 h at rt, then incubated with anti-HPSE 709 
(AbCam ab59787) or anti-GUSB (AbCam ab103112) at 1:1000 dilution in 5% BSA at 4 qC overnight. 710 
Membranes were washed 3 u with TBST (50 mM Tris [pH 7.5], 150 mM NaCl, 0.05% Tween 20), then 711 
incubated with HRP conjugated goat-anti-rabbit (Sigma A0545) at 1:5000 dilution in 5% BSA for 1 h 712 
at room temperature.  Membranes were washed again 3 u with TBST, blots visualized using 713 
Amersham prime ECL reagent (GE Healthcare), and recorded using a Bio-Rad ChemiDoc XRS.  Full-714 
length images of all blots used in this study can be found in Supplementary Fig. 12. 715 
Protein crystallization  716 
AcGH79 717 
AcGH79 was tested against a range of commercial crystallization screens. Well diffracting crystals of 718 
wild type AcGH79 were obtained by the sitting drop vapor diffusion method at 20 qC using 0.8 ?1.2 M 719 
0.5:9.5 NaH2PO4:K2HPO4 (v/v) at a protein:well ratio of 700:500 nL. Crystals of AcGH79 E287Q 720 
mutant were obtained using 1.2 ?1.5 M 1.0:9.0 NaH2PO4:K2HPO4 (v/v) at a protein:well ratio of 721 
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500:500 nL. Crystals typically appeared after 1 day.  Crystals were cryoprotected using 2 M lithium 722 
sulfate prior to flash freezing in liquid N2 for data collection.   723 
Mature HPSE 724 
Mature HPSE was crystallized and data collected as previously described8. 725 
proHPSE 726 
proHPSE at 10 mg/mL was tested against a range of commercial crystallization screens. Thin plate 727 
crystals were found in the JCSG screen, which were used to microseed subsequent rounds of crystal 728 
screening52.  Well diffracting single crystals were obtained by the sitting drop vapor diffusion method 729 
at 20 qC using 100 mM succinate [pH 7.0], 17% PEG3350 and 1:250 diluted seed stock at a 730 
protein:seed:well ratio of 700:100:400 nL.  Crystals typically appeared after 1 day and grew to 731 
maximum size within 10 days. proHPSE crystals were cryoprotected using mother liquor solution 732 
supplemented with 25% ethylene glycol prior to flash freezing in liquid N2 for data collection.   733 
Xray data collection and structure solution 734 
Xray diffraction data were collected at 100 K at beamlines i02 (5LA4, 5LA7), i03 (5G0Q, 5L77, 5L9Y) 735 
and i04 (5L9Z) of the Diamond Light Source UK.  Reflections were autoprocessed with the xia2 736 
pipeline53 of the CCP4 software suite, or manually processed using XDS54 and Aimless55.  Apo 737 
proHPSE was solved by molecular replacement with the mature HPSE model (5E8M) using MolRep56, 738 
followed by alternating rounds of manual model building and refinement using Coot and REFMAC5 739 
respectively57,58.  740 
For all complexes with ABP 5, crystals were soaked in their respective mother liquors supplemented 741 
with 2 ?5 mM 5 for 1 ?3 h at 20 qC.  Soaked crystals were cryoprotected using their respective 742 
cryoprotectant solutions prior to flash freezing in liquid N2 for data collection. 743 
Complexes were solved by molecular replacement with their respective apo structures, followed by 744 
rounds of manual model building and refinement using Coot and REFMAC5. Ligand coordinates were 745 
built using jLigand59.  Active site diagrams were generated using ccp4mg60.  Ribbon and protein 746 
surface diagrams were generated using PyMOL. 747 
Accession codes 748 
Coordinates and structure factors have been deposited in the Protein Data Bank under accession 749 
codes 5G0Q (AcGH79(wt)-5 complex), 5L77 (AcGH79(E287Q)-5 complex), 5L9Y (HPSE(wt)-5 750 
complex), 5L9Z (HPSE(E343Q)-5 complex), 5LA4 (apo proHPSE), 5LA7 (proHPSE-5 complex).   751 
Data availability 752 
All other data generated or analyzed during this study are included in this published article (and its 753 
Supplementary Information files), or are available from the corresponding authors on reasonable 754 
request. 755 
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